Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids

Sharon Anavi-Goffer*, Gemma Baillie, Andrew Irving, Juerg Gertsch, Iain R. Greig, Roger G. Pertwee, Ruth A. Ross

*Corresponding author for this work

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

GPR55 is activated by l-a-lysophosphatidylinositol (LPI) but also by certain cannabinoids. In this study, we investigated the GPR55 pharmacology of various cannabinoids, including analogues of the CB1 receptor antagonist Rimonabant®, CB2 receptor agonists, and Cannabis sativa constituents. To test ERK1/2 phosphorylation, a primary downstream signaling pathway that conveys LPI-induced activation of GPR55, a high throughput system, was established using the AlphaScreen® SureFire® assay. Here, we show that CB1 receptor antagonists can act both as agonists alone and as inhibitors of LPI signaling under the same assay conditions. This study clarifies the controversy surrounding the GPR55-mediated actions of SR141716A; some reports indicate the compound to be an agonist and some report antagonism. In contrast, we report that the CB2 ligand GW405833 behaves as a partial agonist of GPR55 alone and enhances LPI signaling. GPR55 has been implicated in pain transmission, and thus our results suggest that this receptor may be responsible for some of the antinociceptive actions of certain CB2 receptor ligands. The phytocannabinoids ¿9-tetrahydrocannabivarin, cannabidivarin, and cannabigerovarin are also potent inhibitors of LPI. These Cannabis sativa constituents may represent novel therapeutics targeting GPR55
Original languageEnglish
Pages (from-to)91-104
Number of pages15
JournalThe Journal of Biological Chemistry
Volume287
Issue number1
Early online date25 Oct 2011
DOIs
Publication statusPublished - 2 Jan 2012

Keywords

  • allosteric regulation
  • cannabinoid receptors
  • cannabinoids
  • G protein-coupled receptors (GPCR)
  • pharmacology
  • acomplia
  • AlphaScreen
  • bitopic ligand
  • GPR55
  • PLX-4720 BRAF inhibitor

Cite this

Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. / Anavi-Goffer, Sharon; Baillie, Gemma; Irving, Andrew; Gertsch, Juerg; Greig, Iain R.; Pertwee, Roger G.; Ross, Ruth A.

In: The Journal of Biological Chemistry, Vol. 287, No. 1, 02.01.2012, p. 91-104.

Research output: Contribution to journalArticle

Anavi-Goffer, Sharon ; Baillie, Gemma ; Irving, Andrew ; Gertsch, Juerg ; Greig, Iain R. ; Pertwee, Roger G. ; Ross, Ruth A. / Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. In: The Journal of Biological Chemistry. 2012 ; Vol. 287, No. 1. pp. 91-104.
@article{fff1ace8f43c4de282bd403c454d3e8f,
title = "Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids",
abstract = "GPR55 is activated by l-a-lysophosphatidylinositol (LPI) but also by certain cannabinoids. In this study, we investigated the GPR55 pharmacology of various cannabinoids, including analogues of the CB1 receptor antagonist Rimonabant{\circledR}, CB2 receptor agonists, and Cannabis sativa constituents. To test ERK1/2 phosphorylation, a primary downstream signaling pathway that conveys LPI-induced activation of GPR55, a high throughput system, was established using the AlphaScreen{\circledR} SureFire{\circledR} assay. Here, we show that CB1 receptor antagonists can act both as agonists alone and as inhibitors of LPI signaling under the same assay conditions. This study clarifies the controversy surrounding the GPR55-mediated actions of SR141716A; some reports indicate the compound to be an agonist and some report antagonism. In contrast, we report that the CB2 ligand GW405833 behaves as a partial agonist of GPR55 alone and enhances LPI signaling. GPR55 has been implicated in pain transmission, and thus our results suggest that this receptor may be responsible for some of the antinociceptive actions of certain CB2 receptor ligands. The phytocannabinoids ¿9-tetrahydrocannabivarin, cannabidivarin, and cannabigerovarin are also potent inhibitors of LPI. These Cannabis sativa constituents may represent novel therapeutics targeting GPR55",
keywords = "allosteric regulation, cannabinoid receptors, cannabinoids, G protein-coupled receptors (GPCR), pharmacology, acomplia, AlphaScreen, bitopic ligand, GPR55, PLX-4720 BRAF inhibitor",
author = "Sharon Anavi-Goffer and Gemma Baillie and Andrew Irving and Juerg Gertsch and Greig, {Iain R.} and Pertwee, {Roger G.} and Ross, {Ruth A.}",
year = "2012",
month = "1",
day = "2",
doi = "10.1074/jbc.M111.296020",
language = "English",
volume = "287",
pages = "91--104",
journal = "The Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC",
number = "1",

}

TY - JOUR

T1 - Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids

AU - Anavi-Goffer, Sharon

AU - Baillie, Gemma

AU - Irving, Andrew

AU - Gertsch, Juerg

AU - Greig, Iain R.

AU - Pertwee, Roger G.

AU - Ross, Ruth A.

PY - 2012/1/2

Y1 - 2012/1/2

N2 - GPR55 is activated by l-a-lysophosphatidylinositol (LPI) but also by certain cannabinoids. In this study, we investigated the GPR55 pharmacology of various cannabinoids, including analogues of the CB1 receptor antagonist Rimonabant®, CB2 receptor agonists, and Cannabis sativa constituents. To test ERK1/2 phosphorylation, a primary downstream signaling pathway that conveys LPI-induced activation of GPR55, a high throughput system, was established using the AlphaScreen® SureFire® assay. Here, we show that CB1 receptor antagonists can act both as agonists alone and as inhibitors of LPI signaling under the same assay conditions. This study clarifies the controversy surrounding the GPR55-mediated actions of SR141716A; some reports indicate the compound to be an agonist and some report antagonism. In contrast, we report that the CB2 ligand GW405833 behaves as a partial agonist of GPR55 alone and enhances LPI signaling. GPR55 has been implicated in pain transmission, and thus our results suggest that this receptor may be responsible for some of the antinociceptive actions of certain CB2 receptor ligands. The phytocannabinoids ¿9-tetrahydrocannabivarin, cannabidivarin, and cannabigerovarin are also potent inhibitors of LPI. These Cannabis sativa constituents may represent novel therapeutics targeting GPR55

AB - GPR55 is activated by l-a-lysophosphatidylinositol (LPI) but also by certain cannabinoids. In this study, we investigated the GPR55 pharmacology of various cannabinoids, including analogues of the CB1 receptor antagonist Rimonabant®, CB2 receptor agonists, and Cannabis sativa constituents. To test ERK1/2 phosphorylation, a primary downstream signaling pathway that conveys LPI-induced activation of GPR55, a high throughput system, was established using the AlphaScreen® SureFire® assay. Here, we show that CB1 receptor antagonists can act both as agonists alone and as inhibitors of LPI signaling under the same assay conditions. This study clarifies the controversy surrounding the GPR55-mediated actions of SR141716A; some reports indicate the compound to be an agonist and some report antagonism. In contrast, we report that the CB2 ligand GW405833 behaves as a partial agonist of GPR55 alone and enhances LPI signaling. GPR55 has been implicated in pain transmission, and thus our results suggest that this receptor may be responsible for some of the antinociceptive actions of certain CB2 receptor ligands. The phytocannabinoids ¿9-tetrahydrocannabivarin, cannabidivarin, and cannabigerovarin are also potent inhibitors of LPI. These Cannabis sativa constituents may represent novel therapeutics targeting GPR55

KW - allosteric regulation

KW - cannabinoid receptors

KW - cannabinoids

KW - G protein-coupled receptors (GPCR)

KW - pharmacology

KW - acomplia

KW - AlphaScreen

KW - bitopic ligand

KW - GPR55

KW - PLX-4720 BRAF inhibitor

U2 - 10.1074/jbc.M111.296020

DO - 10.1074/jbc.M111.296020

M3 - Article

VL - 287

SP - 91

EP - 104

JO - The Journal of Biological Chemistry

JF - The Journal of Biological Chemistry

SN - 0021-9258

IS - 1

ER -